Research
Liver Cancer Index – The Mapping Survey Is Available Online
The survey was created to map the liver cancer treatment landscape across the EU and is now available online and disseminated among several relevan...
Primary Findings From The GLOW Study Signals Positive Momentum In The Development Of Novel Therapeutic Options For Patients With HER2-Negative Locally Advanced Unresectable Or Metastatic Gastric & GEJ Cancers
At the end of 2022, leaders of the Phase 3 clinical trial GLOW shared their positive primary findings. GLOW (NCT03653507) is a global, multicenter,...
Trastuzumab Deruxtecan Meets Objective Response Rate Endpoint in Several Types of HER2-expressing Advanced Solid Tumours
Positive topline results of the ongoing DESTINY-PanTumour02 Phase II trial (NCT04482309) showed that treatment with trastuzumab deruxtecan met the...
The First International Management Guidelines for Early-Onset Colorectal Cancer
This March, the Clinical Gastroenterology and Hepatology journal published the first management guidelines for Early-Onset Colorectal Cancer (eo-CR...
Imfinzi & Imjudo Immunotherapy Drug Combinations Approved in the EU for the Treatment of Advanced Liver Cancer
The combination of durvalumab (Imfinzi) and tremelimumab (Imjudo) immunotherapies has been approved by the European Commission (EC) for the first-l...
Zolbetuximab Plus Chemotherapy Extends Overall Survival for Patients with Advanced or Metastatic Gastric & Gastro-oesophageal Junction Adenocarcinoma
The Annual American Society of Clinical Oncologists Gastrointestinal Cancers Symposium (ASCO GI) kicked off the year with lots of new data in the f...
DiCE Supports Act4Biosimilars to Increase Patient Access to Biologic Medicines
On 30 January, the Act4Biosimilars initiative hosted a virtual meeting with key stakeholders from across the healthcare space to discuss the Action...
16 February is World Cholangiocarcinoma Day
DiCE is proud to support GCCA’s international effort to raise much-needed awareness of CCA, devastating cancer that occurs in the bile ducts in o...
Interventions to Reduce Cancer Screening Inequities
A group of patients and patient advocacy organisations published a promising multistep strategy to reduce cancer screening inequalities In Internat...
First Immunotherapy Drug Durvalumab Plus Chemotherapy Approved in Europe for Advanced Biliary Cancer
On 21 December the European Commission (EC) approved the use of durvalumab (Imfinzi ®) plus chemotherapy (gemcitabine plus cisplatin) as the first...
